Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis

OBJECTIVE: To determine the duration of clinical benefit among patients with psoriatic arthritis (PsA) discontinuing tumour necrosis factor inhibitor (TNFi) therapy while in low disease activity (LDA), and to identify patient characteristics associated with prolonged clinical benefit. METHODS: We pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, D H, Boyd, T A, Etzel, C J, Cox, V, Kremer, J, Mease, P, Kavanaugh, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5255890/
https://www.ncbi.nlm.nih.gov/pubmed/28123783
http://dx.doi.org/10.1136/rmdopen-2016-000395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5255890/
https://www.ncbi.nlm.nih.gov/pubmed/28123783
http://dx.doi.org/10.1136/rmdopen-2016-000395

Ejemplares similares